Protein folding

Global AL Amyloidosis Epidemiology Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 2, 2020
Biotechnology, General Health, Health, Amyloidosis, Protein folding, AL amyloidosis, Epidemiology

The "AL Amyloidosis - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "AL Amyloidosis - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'AL Amyloidosis - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the AL Amyloidosis, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The disease epidemiology covered in the report provides historical and forecasted AL amyloidosis symptoms epidemiology segmented as the total incident cases of AL amyloidosis, Gender-specific cases of AL amyloidosis, and age-specific cases of AL amyloidosis.
  • The epidemiology segment also provides the AL Amyloidosis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies

Retrieved on: 
Monday, November 30, 2020
Biotechnology, Health, Science, Pharmaceutical, Research, Protein structure, Protein folding

The collaboration will use Wrens network kinetics drug discovery platform, alongside Eisais extensive experience in drug discovery for neurodegenerative disorders, to accelerate the development of clinical candidates.

Key Points: 
  • The collaboration will use Wrens network kinetics drug discovery platform, alongside Eisais extensive experience in drug discovery for neurodegenerative disorders, to accelerate the development of clinical candidates.
  • Wrens proprietary network kinetics drug discovery platform enables an entirely new approach to drug discovery, designed specifically to address the unique challenges associated with protein misfolding diseases.
  • Wren is a spin-off company from the University of Cambridge (UK) and Lund University (Sweden), focused on drug discovery and development for protein misfolding diseases.
  • Wren is using its unique approach to develop a broad pipeline of therapeutics for protein misfolding diseases.

Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies

Retrieved on: 
Monday, November 30, 2020
Branches of biology, Biology, Neurological disorders, Protein folding, Protein structure, Amyloidosis, Neurodegeneration, Proteopathy

Wren possesses a novel network kinetics drug discovery platform that precisely quantifies the effects of small molecules on the protein misfolding and aggregation pathway that causes neurodegenerative diseases.

Key Points: 
  • Wren possesses a novel network kinetics drug discovery platform that precisely quantifies the effects of small molecules on the protein misfolding and aggregation pathway that causes neurodegenerative diseases.
  • The collaboration will use Wren's network kinetics drug discovery platform, alongside Eisai's extensive experience in drug discovery for neurodegenerative disorders, to accelerate the development of clinical candidates.
  • Wren's proprietary network kinetics drug discovery platform enables an entirely new approach to drug discovery, designed specifically to address the unique challenges associated with protein misfolding diseases.
  • Wren is using its unique approach to develop a broad pipeline of therapeutics for protein misfolding diseases.

Attralus to Present Clinical Data at Upcoming Virtual ASH 2020

Retrieved on: 
Thursday, November 5, 2020
Branches of biology, Amyloidosis, Organ systems, Neurological disorders, Protein folding, Anatomy, AL amyloidosis, Familial amyloid polyneuropathy, Transthyretin, Wild-type transthyretin amyloid, Proteopathy

The data will be presented by Dr. Jonathan Wall, an internationally known expert in the amyloidosis field, the co-founder of Attralus, and the scientist behind Attralus' AT-01 technology.

Key Points: 
  • The data will be presented by Dr. Jonathan Wall, an internationally known expert in the amyloidosis field, the co-founder of Attralus, and the scientist behind Attralus' AT-01 technology.
  • The data will provide an update on the detection of AL amyloidosis in patients as well as the differentiation of AL amyloidosis from ATTR amyloidosis, using AT-01 imaging.
  • Presently, there are no approved imaging agents in the U.S. for the diagnosis of systemic amyloidosis, including AL amyloidosis.
  • "We are excited and honored to present additional data on AT-01, our potential first in class diagnostic for amyloidosis, at ASH 2020 this year," said Spencer Guthrie, CEO of Attralus.

ProMIS Neurosciences Closes First Tranche of Private Placement

Retrieved on: 
Thursday, November 5, 2020
Medical specialties, Branches of biology, Microsoft Windows, Vaccination, Protein folding, Promis, Vaccine, Proteopathy, Spotify, Antibody

A second closing (the Final Closing) of the Offering is expected to be completed within a week.

Key Points: 
  • A second closing (the Final Closing) of the Offering is expected to be completed within a week.
  • ProMIS proprietary peptide antigens can also be used to create potential therapeutic antibodies, as well as serve as the basis for development of vaccines.
  • ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
  • To learn more about protein misfolding diseases, listen to Episodes 11, 24, of Saving Minds, a podcast available at iTunes or Spotify.

Fortress Biotech Announces Oral and Poster Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Wednesday, November 4, 2020
Branches of biology, Proteins, Amyloidosis, Protein folding, Immunology, Biology, Amyloid, Histopathology, AL amyloidosis, Antibody

Phase 2 data on Caelum Biosciences (Caelum) CAEL-101 for the treatment of relapsed or refractory amyloid light chain AL amyloidosis will be presented by the Cleveland Clinic during oral and poster sessions.

Key Points: 
  • Phase 2 data on Caelum Biosciences (Caelum) CAEL-101 for the treatment of relapsed or refractory amyloid light chain AL amyloidosis will be presented by the Cleveland Clinic during oral and poster sessions.
  • CAEL-101, which is being developed in a collaboration between Caelum, a company founded by Fortress, and Alexion Pharmaceuticals, Inc., recently progressed into Phase 3 development.
  • Lindsay A. Rosenwald, M.D., Fortress Chairman, President and Chief Executive Officer, said, We are looking forward to data from two of our clinical programs being presented in oral and poster sessions at the ASH Annual Meeting.
  • The antibody is designed to bind to misfolded light chain protein and amyloid and shows binding to both kappa and lambda subtypes.

Prothena Announces Presentations on Two Programs from its Alzheimer’s Disease Portfolio at CTAD 2020

Retrieved on: 
Wednesday, November 4, 2020
Branches of biology, Medical specialties, Biology, Immunology, Amyloidosis, Protein folding, Amyloid beta, Molecular neuroscience, Peptides, Amyloid, Alzheimer's disease, Vaccine

The two programs are part of Prothenas Alzheimers disease portfolio that includes antibodies, vaccines and small molecules.

Key Points: 
  • The two programs are part of Prothenas Alzheimers disease portfolio that includes antibodies, vaccines and small molecules.
  • Monoclonal antibodies targeting key epitopes within the N-terminus of A have demonstrated that reducing amyloid plaque burden is associated with the slowing of clinical decline in Alzheimers disease.
  • The MIV is a single vaccine and is being developed for the prevention and treatment of Alzheimers disease.
  • Prothenas wholly-owned programs include PRX004 for the potential treatment of ATTR amyloidosis, and a portfolio of programs for the potential treatment of Alzheimers disease including PRX012 that targets A (Amyloid beta).

ProMIS Neurosciences adds Dr. David Wishart to its Scientific Advisory Board

Retrieved on: 
Thursday, October 29, 2020
Branches of biology, Medical specialties, Protein folding, Vaccination, Vaccine, Virology, Proteopathy, Biology

The commitment and talent of our advisory board has been instrumental to the ongoing development of our broad portfolio of highly specific therapeutic, vaccine and diagnostic candidates, said Eugene Williams, Executive Chairman of ProMIS Neurosciences.

Key Points: 
  • The commitment and talent of our advisory board has been instrumental to the ongoing development of our broad portfolio of highly specific therapeutic, vaccine and diagnostic candidates, said Eugene Williams, Executive Chairman of ProMIS Neurosciences.
  • With Dr. Wisharts support, ProMIS will continue to expand the application of its platform to the biology of additional misfolded protein diseases.
  • Never before has there been a more urgent need for therapy, diagnostic and vaccine candidates that are highly specific for their intended target, said Dr. Wishart.
  • ProMIS SAB includes distinguished, highly published and cited contributors to the current scientific understanding of Alzheimers, Parkinsons, ALS, protein misfolding diseases in general, vaccines and diagnostics.

ProMIS Neurosciences’ Neil Cashman to Speak at Protein Misfolding Drug Discovery Conference

Retrieved on: 
Tuesday, October 13, 2020
Branches of biology, Neurological disorders, Amyloidosis, Protein folding, Protein structure, Neurodegeneration, Proteopathy, Immunotherapy

These diseases lack effective therapies in large part because classical drug discovery and development approaches cannot selectively target the toxic oligomer with adequate precision.

Key Points: 
  • These diseases lack effective therapies in large part because classical drug discovery and development approaches cannot selectively target the toxic oligomer with adequate precision.
  • At this inaugural conference, intended to help shift this drug design and discovery paradigm, Dr. Cashman will highlight the unique ability of ProMIS proprietary drug discovery and development platform to address this enormous unmet need in his presentation, Precision immunotherapies for protein misfolding diseases: the ProMIS platform.
  • Protein misfolding is a root cause of multiple neurodegenerative diseases, as well as other disease states such as certain cancers, said Dr. Neil Cashman.
  • To learn more about protein misfolding diseases, listen to Episode 15 of the Saving Minds podcast at iTunes or Spotify .

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, October 2, 2020
Branches of biology, Financial markets, Finance, Corporate finance, Histopathology, Structural proteins, Protein folding, Amyloidosis, Amyloid, NASDAQ, Stock, Option

The stock options have an exercise price per share equal to $10.31, which was the closing trading price on October 1, 2020, the date of the grants.

Key Points: 
  • The stock options have an exercise price per share equal to $10.31, which was the closing trading price on October 1, 2020, the date of the grants.
  • The stock options were granted pursuant to the Companys 2020 Employment Inducement Incentive Plan, which was approved by the Companys board of directors under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
  • Prothenas wholly-owned programs include PRX004 for the potential treatment of ATTR amyloidosis, and programs that target A (Amyloid beta) for the potential treatment of Alzheimers disease.
  • For more information, please visit the Companys website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.